

## CORRIGENDUM

### Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

INM Micallef<sup>1</sup>, AD Ho<sup>2</sup>, LM Klein<sup>3</sup>, S Marulkar<sup>4</sup>, PJ Gandhi<sup>4</sup>, G Calandra<sup>5</sup> and PA McSweeney<sup>6</sup>

<sup>1</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA; <sup>2</sup>Department of Internal Medicine, Division of Hematology/Oncology, University of Heidelberg, Heidelberg, Germany; <sup>3</sup>Department of Medicine, Division of Hematology/Oncology, Lutheran General Hospital, Park Ridge, IL, USA; <sup>4</sup>Genzyme Corporation, Cambridge, MA, USA; <sup>5</sup>The Commonwealth Medical College, Scranton, PA, USA and <sup>6</sup>Rocky Mountain Blood and Marrow Transplant Program, Rocky Mountain Cancer Centers, Denver, CO, USA

*Bone Marrow Transplantation* (2011) **46**, 1398; doi:10.1038/bmt.2010.303

**Correction to:** *Bone Marrow Transplantation* (2011) **46**, 350–355; doi:10.1038/bmt.2010.118

of author names. The correct author list and affiliations are shown above.

Since the publication of this article the authors have noticed that G Calandra was omitted from the list

The authors apologize for any inconvenience caused.